Propel:

• To maintain patency following ethmoid sinus surgery.

Sinuva:

• Chronic rhinosinusitis with nasal polyps in patients who have had ethmoid sinus surgery.

Contraindicated in:

• Hypersensitivity to mometasone or any of the copolymers present in implant
• Nasal ulcers or trauma.

Use Cautiously in:

• OB: Safety not established in pregnancy
• Lactation: Safety not established in breastfeeding
• Pedi: Safety and effectiveness not established in children.

EENT: epistaxis, nasal perforation.

Neuro: headache.

Resp: sinusitis, bronchitis.
Misc: foreign body reaction, TOXIC SHOCK SYNDROME.

Drug-Drug:

• Strong CYP3A4 inhibitors, including ketoconazole may ↑ levels and risk of toxicity.

• Implant (Sinuva): 1350 mcg in a bioabsorbable copolymer sinus implant;

• Sinus implant (Adults): One implant (1350 mcg) placed endoscopically.

Sinuva

• Stabilizes and separates nasal mucosal tissues, prevents obstruction caused by adhesions and decreases edema.

• Decreased need for postoperative interventions such as lysis of adhesions and/or the need for corticosteroids.
• Reduction in nasal obstruction/congestion and quantity of nasal polyps.

Therapeutic Classification: corticosteroids, allergy, cold and cough remedies

Pharmacologic Classification: corticosteroids

Absorption: Action is local.

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP3A4 isoenzyme.

Half-life: Unknown.

• Explain purpose, procedure for placement of implant, and postoperative care.
• Frequent use of saline sprays, rinses, or irrigations is recommended postoperatively.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

moe-MET-a-sone